Retension Pharmaceuticals (NASDAQ:RTSN) Stock: Insider Eric Keller Buys 20,800 Shares

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN – Get Free Report) CEO Eric Keller purchased 20,800 shares of the stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average cost of $12.00 per share, with a total value of $249,600.00. Following the acquisition, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. This represents a 5.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Retension Pharmaceuticals Stock Performance

RTSN stock opened at $11.64 on Thursday. Retension Pharmaceuticals, Inc. has a fifty-two week low of $9.66 and a fifty-two week high of $12.50.

Get Retension Pharmaceuticals alerts:

Retension Pharmaceuticals Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

See Also

• Five stocks we like better than Retension Pharmaceuticals
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
• PBF Energy’s Stunning Rally Faces a Critical Test
• Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.